A detailed history of Legal & General Group PLC transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 321,430 shares of CRL stock, worth $62.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
321,430
Previous 321,430 -0.0%
Holding current value
$62.4 Million
Previous $63.3 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$187.96 - $245.29 $1.47 Million - $1.92 Million
7,841 Added 2.5%
321,430 $63.3 Million
Q2 2024

Aug 14, 2024

SELL
$206.39 - $268.73 $2.64 Million - $3.43 Million
-12,773 Reduced 3.91%
313,589 $64.8 Million
Q1 2024

Jul 01, 2024

BUY
$203.52 - $273.43 $1.06 Million - $1.42 Million
5,195 Added 1.62%
326,362 $88.4 Million
Q1 2024

May 14, 2024

SELL
$203.52 - $273.43 $2.14 Million - $2.88 Million
-10,527 Reduced 3.17%
321,167 $87 Million
Q4 2023

Feb 15, 2024

BUY
$164.52 - $238.84 $6.66 Million - $9.66 Million
40,452 Added 13.89%
331,694 $78.4 Million
Q3 2023

Nov 14, 2023

SELL
$194.44 - $217.61 $2.53 Million - $2.83 Million
-13,024 Reduced 4.28%
291,242 $57.1 Million
Q2 2023

Aug 14, 2023

SELL
$183.71 - $210.25 $448,436 - $513,220
-2,441 Reduced 0.8%
304,266 $64 Million
Q1 2023

May 15, 2023

BUY
$191.89 - $259.92 $1.07 Million - $1.45 Million
5,580 Added 1.85%
306,707 $61.9 Million
Q4 2022

Feb 14, 2023

SELL
$197.11 - $250.07 $2.54 Million - $3.22 Million
-12,862 Reduced 4.1%
301,127 $65.6 Million
Q3 2022

Nov 14, 2022

SELL
$182.44 - $250.54 $566,658 - $778,177
-3,106 Reduced 0.98%
313,989 $61.8 Million
Q2 2022

Aug 22, 2022

BUY
$204.13 - $302.4 $632,394 - $936,835
3,098 Added 0.99%
317,095 $67.8 Million
Q1 2022

May 16, 2022

BUY
$255.51 - $362.11 $2.88 Million - $4.08 Million
11,273 Added 3.72%
313,997 $89.2 Million
Q4 2021

Feb 14, 2022

SELL
$351.38 - $448.68 $4.11 Million - $5.25 Million
-11,693 Reduced 3.72%
302,724 $114 Million
Q3 2021

Nov 15, 2021

BUY
$372.64 - $458.3 $38.7 Million - $47.6 Million
103,789 Added 49.28%
314,417 $130 Million
Q2 2021

Aug 12, 2021

BUY
$294.17 - $371.65 $32.5 Million - $41.1 Million
110,590 Added 110.55%
210,628 $77.9 Million
Q1 2021

May 17, 2021

BUY
$249.67 - $299.48 $2.45 Million - $2.94 Million
9,827 Added 10.89%
100,038 $29 Million
Q4 2020

Feb 12, 2021

SELL
$222.0 - $252.62 $576,534 - $656,054
-2,597 Reduced 2.8%
90,211 $22.5 Million
Q3 2020

Nov 13, 2020

BUY
$175.56 - $226.45 $850,412 - $1.1 Million
4,844 Added 5.51%
92,808 $21 Million
Q2 2020

Aug 14, 2020

BUY
$118.84 - $189.72 $1.01 Million - $1.61 Million
8,472 Added 10.66%
87,964 $15.3 Million
Q1 2020

May 14, 2020

BUY
$98.9 - $178.34 $531,983 - $959,290
5,379 Added 7.26%
79,492 $10.1 Million
Q4 2019

Feb 13, 2020

BUY
$126.05 - $152.76 $663,275 - $803,823
5,262 Added 7.64%
74,113 $11.3 Million
Q3 2019

Nov 13, 2019

BUY
$125.07 - $143.67 $478,267 - $549,394
3,824 Added 5.88%
68,851 $9.11 Million
Q2 2019

Aug 14, 2019

BUY
$123.4 - $148.55 $26,160 - $31,492
212 Added 0.33%
65,027 $9.23 Million
Q1 2019

May 15, 2019

BUY
$104.82 - $146.73 $301,881 - $422,582
2,880 Added 4.65%
64,815 $9.41 Million
Q4 2018

Feb 15, 2019

BUY
$105.09 - $137.23 $196,728 - $256,894
1,872 Added 3.12%
61,935 $7.01 Million
Q3 2018

Nov 20, 2018

SELL
$112.11 - $134.54 $5,829 - $6,996
-52 Reduced 0.09%
60,063 $8.08 Million
Q2 2018

Aug 10, 2018

SELL
$102.37 - $117.25 $106,771 - $122,291
-1,043 Reduced 1.71%
60,115 $6.75 Million
Q1 2018

May 17, 2018

BUY
$98.19 - $115.2 $799,561 - $938,073
8,143 Added 15.36%
61,158 $6.53 Million
Q4 2017

Feb 13, 2018

BUY
$100.43 - $118.09 $5.32 Million - $6.26 Million
53,015
53,015 $5.8 Million

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $9.88B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.